Skip to main content

CM Life Sciences III, Inc. (CMLT)

NASDAQ: CMLT · Delayed Price · USD
9.92
-0.01 (-0.05%)
After-hours:Sep 20, 2021 4:00 PM EDT
9.93
0.02 (0.15%)
At close: Sep 20, 3:02 PM
Market Cap575.65M
Revenue (ttm)n/a
Net Income (ttm)n/a
Shares Out58.00M
EPS (ttm)n/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume55,119
Open9.92
Previous Close9.91
Day's Range9.90 - 9.95
52-Week Range9.81 - 11.10
Betan/a
Analystsn/a
Price Targetn/a
Est. Earnings Daten/a

About CMLT

CM Life Sciences III is a newly organized blank check company incorporated for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. While we may pursue an initial business combination target in any industry, sector or geographic region, we intend to capitalize on our management team’s background and experience to identify promising opportunities in the life sciences sector. Eli Casdin, our Chief Executive Officer, founded Casdi...

IndustryShell Companies
IPO DateApr 7, 2021
Stock ExchangeNASDAQ
Ticker SymbolCMLT
Full Company Profile

News

EQRx Announces Presentation of Phase 3 Data Demonstrating a Progression-Free Survival Benefit with Sugemalimab Consol...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--EQRx, a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, today announced a late...

3 days ago - Business Wire

EQRx Announces Presentation of Updated Data from Pivotal Phase 3 Study of Anti-PD-L1 Antibody Sugemalimab in Combinat...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--EQRx, a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, today announced a late...

6 days ago - Business Wire

EQRx to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--EQRx, a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, today announced that A...

1 week ago - Business Wire

Corvex, Casdin Backed SPAC To Merge With EQRx In $1.8B Deal

CM Life Sciences III Inc (NASDAQ: CMLT), the third SPAC backed by Eli Casdin's Casdin Capital LLC and Keith Meister's Corvex Management LP, is set to merge with EQRx Inc (NASDAQ: EQRX). The stock will l...

1 month ago - Benzinga

Here are the benefits of SPAC deals

Eli Casdin, the chief investment officer of Casdin Capital, joins Keith Meister, CEO of Corvex Management, on the Halftime Report to discuss their SPAC deal with EQRX, a biotechnology company.

1 month ago - CNBC Television

EQRx to Accelerate Growth with $1.8 Billion Raise through Proposed Combination with CM Life Sciences III

CAMBRIDGE, Mass. & NEW YORK--(BUSINESS WIRE)--EQRx, Inc., a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, and C...

1 month ago - Business Wire

CM Life Sciences III Inc. Announces Separate Trading of Its Shares of Class A Common Stock and Warrants, on or About ...

NEW YORK--(BUSINESS WIRE)--CM Life Sciences III Inc. (Nasdaq: CMLTU) (the “Company”) today announced that holders of the Company's units sold in its initial public offering may elect to separately trade...

3 months ago - Business Wire

Tech Moves: Adaptive Biotech co-founders join life sciences SPAC; new edtech execs; and more

— Adaptive Biotechnologies co-founders and brothers Chad and Harlan Robins are among the directors of a new life sciences SPAC.

5 months ago - GeekWire

CM Life Sciences III Inc., Sponsored by Affiliates of Casdin Capital and Corvex Management, Announces Closing of $552...

NEW YORK--(BUSINESS WIRE)--CM Life Sciences III Inc. (the “Company”) announced today that it closed its initial public offering of 55,200,000 units at $10.00 per unit, including 7,200,000 units issued p...

5 months ago - Business Wire

CM Life Sciences III Inc., Sponsored by Affiliates of Casdin Capital and Corvex Management, Announces Pricing of Upsi...

CM Life Sciences III Inc. (the “Company”) announced today that it priced its initial public offering of 48,000,000 units at $10.00 per unit.

5 months ago - Business Wire

Casdin Capital and Corvex Management's SPAC CM Life Sciences III files for a $400 million IPO

CM Life Sciences III, the third blank check company formed by Casdin Capital and Corvex Management targeting a life science business, filed on Thursday with the SEC to raise up to $400 million in an ini...

6 months ago - NASDAQ

CM Life Sciences III IPO Registration Document (S-1)

CM Life Sciences III, Inc. has filed to go public with an IPO on the NASDAQ.

6 months ago - SEC